EUVIMEDEUVIMED entdecken
Crossref

Discovery, Optimization, and Evaluation of Novel Pyridin-2(1 H )-one Analogues as Potent TRK Inhibitors for Cancer Treatment

Zichao Xu, Xia Peng, Renjie Zhang, Yinchun Ji, Mengke You, Danyi Wang, Yanyan Shen, Mingyue Zheng iD, Chunpu Li iD, Jing Ai, Hong Liu iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Zichao Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Shanghai Tech University, Shanghai 200031, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Youth Innovation Promotion Association of the Chinese Academy of Sciences, National Natural Science Foundation of China, Lingang Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tropomyosin receptor kinase (TRK) fusion, an oncogenic form of kinase with pan-tumor occurrence, is a clinically validated important antitumor target. In this study, we screened our in-house kinase inhibitor library against TRK and identified a promising hit compound 4 with a novel pyridin-2(1H)-one scaffold. Through a combination of structure-based drug design and structure-activity relationship (SAR) study, compound 14q was identified as a potent TRK inhibitor with good kinase selectivity. It also blocked cellular TRK signaling, thereby inhibiting TRK-dependent cell viability. Additionally, 14q displayed acceptable pharmacokinetic properties with 37.8% oral bioavailability in mice. Strong in vivo tumor growth inhibition of 14q was observed in subcutaneous M091 and KM12 tumor xenograft models with TRK fusion, causing significant tumor inhibition or even complete tumor regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsAnimalsHumansMiceProtein Kinase InhibitorsReceptor, trkASignal TransductionStructure-Activity RelationshipPyridones

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsReceptor, trkAPyridones

Autor:innen und Institutionen

  • School of Life Science and Technology, Shanghai Tech University, Shanghai 200031, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • University of Chinese Academy of Sciences, Beijing 100049, China.
  • School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China.

ORCID-Profile: Mingyue Zheng, Chunpu Li, Hong Liu

Förderung

  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • National Natural Science Foundation of China
  • Lingang Laboratory
  • SA-SIBS Scholarship Program
  • Shanghai Municipal Commission of Health and Family Planning

Zitieren

APA

Xu, Z., Peng, X., Zhang, R., Ji, Y., You, M., Wang, D., Shen, Y., Zheng, M., Li, C., Ai, J., & Liu, H. (2024). Discovery, Optimization, and Evaluation of Novel Pyridin-2(1 H )-one Analogues as Potent TRK Inhibitors for Cancer Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01645

Vancouver

Xu Z, Peng X, Zhang R, Ji Y, You M, Wang D, et al. Discovery, Optimization, and Evaluation of Novel Pyridin-2(1 H )-one Analogues as Potent TRK Inhibitors for Cancer Treatment. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01645

BibTeX
@article{Xu2024,
  author = {Xu, Zichao and Peng, Xia and Zhang, Renjie and Ji, Yinchun and You, Mengke and Wang, Danyi and Shen, Yanyan and Zheng, Mingyue and Li, Chunpu and Ai, Jing and Liu, Hong},
  title = {Discovery, Optimization, and Evaluation of Novel Pyridin-2(1 H )-one Analogues as Potent TRK Inhibitors for Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01645}
}
Kostenlos starten →